Samsung Bioepis races to get biosimilar drugs on the market
Korean conglomerate hopes its biopharmaceuticals push can help offset a slowing smartphone market
Wed, Jun 08, 2016 - 5:50 AM
Bioepis employees at its laboratory in Incheon. To quickly get up to speed in an unfamiliar industry, Samsung enlisted drugmaker Biogen as a Bioepis shareholder, scouted industry veterans from firms such as Novartis and Eli Lilly and surrounded them with young recruits.
AS Samsung Bioepis raced to be first to market with a copy of Enbrel, a blockbuster rheumatoid arthritis drug, countdown clocks reminded workers: heading for lunch, meetings or even the washroom: of the days to the first mass production run.